1.2200
+0.0040
+(0.33%)
At close: January 10 at 3:37:14 PM GMT+1
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | 1 |
| Avg. Estimate | -- | -- | 4.6M | 7.1M |
| Low Estimate | -- | -- | 4.6M | 7.1M |
| High Estimate | -- | -- | 4.6M | 7.1M |
| Year Ago Sales | -- | -- | 4.6M | 4.6M |
| Sales Growth (year/est) | -- | -- | 0.00% | 54.35% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| 609.SG | -- | -- | -- | -- |
| S&P 500 | 8.66% | 11.51% | 14.05% | 13.39% |
Related Tickers
PI3.SG Gubra AS
89.80
-1.97%
PI3.DU Gubra AS
89.80
-0.44%
NAMSW NewAmsterdam Pharma Company N.V.
14.78
+3.50%
POLB.L Poolbeg Pharma PLC
5.15
-8.04%
SNGX Soligenix, Inc.
3.2000
-2.14%
GUBRA.CO Gubra A/S
666.00
-1.48%
AUTL Autolus Therapeutics plc
2.3600
-2.07%
ZYME Zymeworks Inc.
13.22
-6.44%
CVM CEL-SCI Corporation
0.4252
+16.05%
MAIA MAIA Biotechnology, Inc.
2.1200
-0.47%